Document is current
Any future updates will be listed below
-
Authors
Izutsu, Koji https://orcid.org/0000-0001-9129-8057
Ando, Kiyoshi
Nishikori, Momoko
Shibayama, Hirohiko
Goto, Hideki
Kuroda, Junya
Kato, Koji
Imaizumi, Yoshitaka
Nosaka, Kisato
Sakai, Rika
Abe, Maho
Hojo, Seiichiro
Nakanishi, Tadashi
Rai, Shinya
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03456726 at ClinicalTrials.govDocuments that mention this clinical trial
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study
https://doi.org/10.1007/s12185-024-03834-9
-
Funding
Funding for this research was provided by:
Eisai Co., Ltd.
- License Information
-
More Information
Article History
Received: 27 March 2024
Revised: 24 July 2024
Accepted: 6 August 2024
First Online: 23 August 2024
Declarations
:
: Koji Izutsu received research funding from Eisai Co., Ltd., related to the submitted work; received research funding from Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Incyte Biosciences Japan G.K., Genmab K.K., Loxo Oncology, Inc., Daiichi Sankyo Co., Ltd., BeiGene, Inc., AbbVie G.K., AstraZeneca K.K., Regeneron Pharmaceuticals, Inc., Yakult Honsha Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K., Pfizer Inc., MSD K.K., Bayer Yakuhin, Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Gilead Sciences, Inc., and Amgen Astellas BioPharma K.K.; consulting fees from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., AbbVie G.K., Takeda Pharmaceutical Co., Ltd., Zenyaku Holdings Co., Ltd., Genmab K.K., Kyowa Kirin Co., Ltd., MSD K.K., Carna Biosciences, Inc., Novartis Pharma K.K., Yakult Honsha Co., Ltd., Nippon Shinyaku Co., Ltd., and BeiGene, Inc.; honoraria from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., SymBio Pharmaceuticals Ltd., Bristol-Myers Squibb K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., AbbVie G.K., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Genmab K.K., Kyowa Kirin Co., Ltd., MSD K.K., Astellas Pharma Inc., Pfizer Inc., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Nippon Kayaku Co., Ltd., and Gilead Sciences, Inc., outside the submitted work. Kiyoshi Ando received research funding from Eisai Co., Ltd., related to the submitted work; received research funding from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Astellas Pharma Inc., Asahi Kasei Pharma Corp., and Otsuka Pharmaceutical Co., Ltd.; honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., and Eisai Co., Ltd., outside the submitted work. Momoko Nishikori received research funding from Eisai Co., Ltd., related to the submitted work; received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and SymBio Pharmaceuticals Ltd.; honoraria from Novartis Pharma K.K., AbbVie G.K., Bristol-Myers Squibb K.K., Gilead Sciences, Inc., Genmab K.K., SymBio Pharmaceuticals Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Sumitomo Pharma Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd., outside the submitted work. Hirohiko Shibayama received research funding from Eisai Co., Ltd., related to the submitted work; received research funding from Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., and AbbVie G.K.; honoraria from Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Sanofi K.K., Fujimoto Pharmaceutical Corporation, Meiji Seika Pharma Co., Ltd., and Nippon Shinyaku Co., Ltd.; is an advisory board member of Chugai Pharmaceutical Co., Ltd., AbbVie G.K., Ono Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K., outside the submitted work; and is an editorial board member of International Journal of Hematology. Hirohiko Shibayama is the editor of International Journal of Hematology. Hideki Goto received honoraria from Novartis Pharma K.K., Kyowa Kirin Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; payment for expert testimony from Sanofi K.K., SymBio Pharmaceuticals Ltd., Bristol-Myers Squibb K.K., and Kyowa Kirin Co., Ltd., outside the submitted work. Junya Kuroda received research funding from Eisai Co., Ltd., related to the submitted work; received research funding from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Japan Blood Products Organization; consulting fees from Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Pfizer Inc., AbbVie G.K., and BeiGene, Inc.; honoraria from Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Sanofi K.K., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Eisai Co., Ltd., AbbVie G.K., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Amgen K.K., and Otsuka Pharmaceutical Co., Ltd., outside the submitted work. Koji Kato received research funding from Eisai Co., Ltd., related to the submitted work; received research funding from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie G.K., Novartis Pharma K.K., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Celgene K.K., Ono Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd, Daiichi Sankyo Co., Ltd., MSD K.K., Bristol-Myers Squibb K.K., Gilead Sciences, Inc., and Astellas Pharma Inc.; honoraria from Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Meiji Seika Pharma Co., Ltd., outside the submitted work. Yoshitaka Imaizumi received honoraria from Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., SymBio Pharmaceuticals Ltd., Sanofi K.K., Bristol-Myers Squibb K.K., Meiji Seika Pharma Co., Ltd., AstraZeneca K.K., and Chugai Pharmaceutical Co., Ltd., outside the submitted work. Kisato Nosaka received research funding from Kyowa Kirin Co., Ltd. and Chugai Pharmaceutical Co., Ltd.; honoraria from Meiji Seika Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., AbbVie G.K., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Ohara Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K., outside the submitted work. Rika Sakai received research funding from Eisai Co., Ltd., related to the submitted work; research funding from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd.; honoraria from Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., SymBio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., CSL Behring K.K., Eisai Co., Ltd., Nippon Shinyaku Co., Ltd., Bristol-Myers Squibb K.K., Mundipharma K.K., Nihon Medi-Physics Co., Ltd., Chugai Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Sanofi K.K., Towa Pharmaceutical Co., Ltd., Sekisui Medical Co., Ltd., and Daiichi Sankyo Co., Ltd., outside the submitted work. Maho Abe, Seiichiro Hojo, and Tadashi Nakanishi are employees of Eisai Co., Ltd. Shinya Rai had no conflict of interest to be declared.
